

Table 4.13.3: Recommendations for pneumococcal vaccination using 23vPPV for adults who *do not* have a condition(s) associated with an increased risk of invasive pneumococcal disease (IPD)*

Non-Indigenous adults			
Current age (years)	1st dose of 23vPPV	2nd dose of 23vPPV (1st revaccination)	3rd dose of 23vPPV (2nd revaccination)
18 to <65 years	Not recommended	Not recommended	Not recommended
≥65 years	Give now	Not recommended	Not recommended
Indigenous adults			
Current age (years)	1st dose of 23vPPV	2nd dose of 23vPPV (1st revaccination)	3rd dose of 23vPPV (2nd revaccination)
18 to <50 years	Not recommended [†]	Not recommended	Not recommended
≥50 years	Give now ^{†‡}	5 years after 1st dose ^{†‡}	Not recommended

* See List 4.13.1 for conditions associated with an increased risk of IPD. Recommendations for those who have a condition(s) that places them at an increased risk of IPD are listed in the text below.

† In the Northern Territory, a dose of 23vPPV is provided to all Indigenous adolescents at approximately 15 years of age, based on the very high prevalence of conditions associated with an increased risk of IPD and incidence of IPD in this sub-population. This dose should be considered a dose received in adulthood for the purpose of limiting the total lifetime number of 23vPPV doses to 3.

‡ The minimum interval between any 2 doses of 23vPPV should be 5 years, and no more than 3 lifetime adult doses of 23vPPV are recommended.